Clinical Trials Sponsored by Eisai Inc.

Total 35627 results

Eisai Inc.

Completed

A Five-Treatment-Period Study to Evaluate the Single-Dose Pharmacokinetics and Pharmacodynamics of Avatrombopag in Healthy Japanese and White Subjects

Thrombocytopenia

United States
Eisai Inc.

Completed

Evaluating the Efficacy and Safety of Zonisamide in the Treatment of Partial Seizures

Partial Seizures

China
Eisai Inc.

Completed

A Study Versus E2020 10mg Followed by an Open-label Extension Phase to Explore the Safety of E2020 SR 23 mg in Japanese Subjects With Severe Alzheimer's Type Dementia

Alzheimer's Type Dementia

Japan
Eisai Inc.

Completed

Evaluation of the Efficacy and Safety of Adjunctive Zonisamide vs Replacement With Zonisamide of the Last Added Antiepileptic Drug

Partial Seizures

Italy
Eisai Inc.

Completed

Evaluating E7389 in Patients With Hormone Refractory Prostate Cancer With Advanced and/or Metastatic Disease Stratified by Prior Chemotherapy

Prostate Cancer

United States
Eisai Inc.

Completed

Randomized, Placebo-controlled Study to Evaluate Effects of E5555 on Renal Function Parameters and OCT2 Activity

Healthy Subjects

United States
Eisai Inc.

Completed

A Study to Evaluate the Safety and Efficacy of Zonisamide an Antiepileptic Drug as Monotherapy or Adjunctive Therapy in Treatment of Adult Patients With Partial, Generalized or Combined Seizures.

Partial, Generalized and Combined Seizures

India
Eisai Inc.

Completed

A 28-Week Open Label Extension Study Evaluating Safety and Tolerability of Donepezil Hydrochloride in Subjects With Mild Cognitive Impairment

Mild Cognitive Impairment

United States
Eisai Inc.

Withdrawn

A Phase 3 Trial of E7777 in Combination With CHOP Compared With CHOP Alone for the First-Line Treatment of Peripheral T-cell Lymphoma

Peripheral T-Cell Lymphoma

United States
Eisai Inc.

Completed

A Study to Evaluate the Effect on 24-hour, Intragastric pH of RAB ER 50-mg Capsules Compared With Esomeprazole (Nexium) 40 mg Capsules and Rabeprazole (Aciphex) 20-mg Tablets

Healthy

United States
Eisai Inc.

Completed

A Study in Healthy Subjects to Evaluate Bioavailability of 4 Formulations of E5501

Idiopathic Thrombocytopenic Purpura

United Kingdom
Eisai Inc.

Completed

A Open-label, Three-period, Partial-replicate Design Study to Evaluate the Inter- and Intrasubject Variability of the Avatrombopag To-be-marketed Formulation Administered as Single Doses of 40 mg to Healthy Subjects Receiving a Low-fat Meal

Healthy Volunteers

United States
Eisai Inc.

Completed

An Study to Determine the Bioavailability of E2609 Tablets Compared to Capsules and the Effect of Food on Absorption

Alzheimer's Disease

United States
Eisai Inc.

Completed

Efficacy, Safety, and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients With Motor Fluctuations

Parkinson's Disease

United States, Canada
Eisai Inc.

Completed

A Study for Evaluating the Efficacy and Safety of Zonisamide and Lamotrigine (Lamictal) for Subjects With Refractory Simple Partial, Complex Partial or Partial With Secondary Generalized Seizures

Epilepsy

China
Eisai Inc.

Completed

Study of Decitabine for Treatment of Older Patients With Acute Myeloid Leukemia (AML)

Acute Myeloid Leukemia

United States
Eisai Inc.

Completed

Efficacy and Safety of Adjunctive Zonisamide in Paediatric Partial Onset Seizures (CATZ Study)

Epilepsy; Paediatric Partial Onset Seizures

Belgium, France, Italy, Spain, Estonia, Hungary, Poland, Ukraine, Latvia
Eisai Inc.

Completed

Dose-Tolerability Titration Study to Evaluate The Efficacy And Safety Of Perampanel (E2007) In Patients With Post-Herpetic Neuralgia (PHN)

Neuralgia

United States, Canada
Eisai Inc.

Terminated

A Study of E2007 In Patients With Parkinson's Disease

Parkinson's Disease

United States
Eisai Inc.

Completed

Irofulven Compared With Fluorouracil in Treating Patients With Pancreatic Cancer

Pancreatic Cancer

United States
Eisai Inc.

Completed

Demonstrate Bioequivalence Between 3 x 2-mg Tablets of Perampanel and a Single 6-mg Tablet of Perampanel in Healthy Subjects

Healthy

United States
Eisai Inc.

Completed

Single and Multiple Dose Asian Bridging Study

Healthy Subjects

United States
Eisai Inc.

Completed

Phase II Study Of E7389, Halichondrin B Analogue, In Patients With Advanced Non-Small Cell Lung Cancer, NSCLC, Who Progressed During Or After Platinum-Based Doublet Chemotherapy

Non-Small-Cell Lung Carcinoma

United States
Eisai Inc.

Completed

A Study of ONTAK in Patients With Relapsed or Refractory, B-Cell Non Hodgkin's Lymphoma

Lymphoma, B-Cell

United States
Eisai Inc.

Completed

Subject Variability in Two Lots of E5501 Administered to Fed and Fasted Healthy Subjects

Purpura, Thrombocytopenic, Idiopathic | Chronic Thrombocytopenia | Acute Idiopathic Thrombocytopenic Purpura

Netherlands
Eisai Inc.

Completed

Trial of Decitabine in Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome

Myelodysplastic Syndrome | Acute Myelogenous Leukemia

United States
Eisai Inc.

Completed

Dose Response Study of Zonegran in Patients With Newly Diagnosed Epilepsy

Epilepsy, Complex Partial

United States, Estonia, Ukraine, Hungary, Lithuania
Eisai Inc.

Completed

Pharmacokinetic Trial of Decitabine (Dacogen) Administered as a 3-hour Infusion to Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome

Leukemia

United States
Eisai Inc.

Suspended

A Dose Escalation Study of E7107 Administered Intravenously on Days 1 and 8 Every 21 Days to Patients With Solid Tumors

Cancer

United States
Eisai Inc.

Completed

GPI 15715 For Sedation in the Intensive Care Unit (ICU) Setting

Intubation | Respiration, Artificial | Postoperative Sedation

United States
Eisai Inc.

Completed

A Safety, Tolerability and Efficacy Study of E7070 in Patients With Renal Cell Carcinoma

Kidney Neoplasms | Carcinoma, Renal Cell | Adenocarcinoma, Renal Cell

United States, France
Eisai Inc.

Recruiting

A Study of E7386 in Combination With Other Anticancer Drug in Participants With Solid Tumor

Neoplasms | Carcinoma, Hepatocellular | Liver Neoplasms | Colorectal Neoplasms | Endometrial Neoplasms

United States, Taiwan, France, Japan, Korea, Republic of
Eisai Inc.

Recruiting

Study of E7386 in Participants With Selected Advanced Neoplasms

Advanced Neoplasms

United States, United Kingdom
Eisai Inc.

Active, not recruiting

A Study to Evaluate the Safety and Tolerability of Lenvatinib in Participants With Advanced or Unresectable Hepatocellular Carcinoma (STELLAR)

Carcinoma, Hepatocellular

United States, Spain, United Kingdom, Australia, Sweden, Italy, Austria, Germany, Portugal, Russian Federation
Eisai Inc.

Completed

Eribulin Mesylate in Combination With Intermittent Erlotinib in Patients With Previously Treated, Advanced Non-Small Cell Lung Cancer

Non-small Cell Lung Cancer

United States, Hong Kong, Taiwan, Korea, Republic of, Singapore, Thailand, Malaysia
Eisai Inc.

Completed

A Double-Blind Study in Healthy Volunteers to Assess the Effect of E7080 on the QTc Interval

Lymphomas | Refractory Solid Tumors

United States
Eisai Inc.

Completed

An Open Label Dose Escalation Study Of E7080

Solid Tumor or Lymphoma

United Kingdom, Netherlands
Eisai Inc.

Completed

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Trial of Lenvatinib (E7080) in 131I-Refractory Differentiated Thyroid Cancer (DTC) (SELECT)

Thyroid Cancer

United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, Czechia, Denmark, France, Germany, Italy, Japan, Korea, Republic of, Poland, Portugal, Romania, Russian Federation, Spain, Sweden, Thailand, United Kingdom
Eisai Inc.

Completed

A Study to Assess Safety, Tolerability, Pharmacokinetics (PK), Immunogenicity, and Pharmacodynamics (PD) of Intravenous Infusions of E2814 in Healthy Participants

Healthy Volunteers

United States
Eisai Inc.

Completed

A Study to Demonstrate the Bioequivalence of Lecanemab Supplied in Vials and a Single-Use Auto-Injector (AI) in Healthy Participants

Healthy Volunteers

United States
Eisai Inc.

Completed

A Phase 1, Multicenter, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of E6201 in Subjects With Advanced Solid Tumors

Advanced Solid Tumors

United States
Eisai Inc.

Completed

A Study in Subjects With Recurrent Malignant Glioma

Glioma

Canada, United States
Eisai Inc.

Completed

A Study of E2027 in Participants With Dementia With Lewy Bodies (DLB) or Parkinson's Disease Dementia (PDD) With or Without Amyloid Copathology

Parkinson Disease | Lewy Body Disease

United States, Canada
Eisai Inc.

Completed

Study Evaluating the Safety and Efficacy of Eribulin Mesilate in Combination With Irinotecan Hydrochloride in Children With Refractory or Recurrent Solid Tumors

Ewing Sarcoma | Rhabdomyosarcoma | Refractory or Recurrent Solid Tumors | Non-Rhabdomyosarcoma Soft Tissue Sarcoma

Spain, United Kingdom, Italy, France, Germany, Greece, Poland, Switzerland
Eisai Inc.

Terminated

A Study to Evaluate the Pharmacodynamic Activity of E2730 in Adult Participants With Photosensitive Epilepsy

Photosensitive Epilepsy

United States
Eisai Inc.

Completed

Rabeprazole Extended-Release 50 mg vs. Ranitidine 150 mg for Maintenance of Healed Erosive Gastroesophageal Reflux Disease (GERD)

Gastroesophageal Reflux Disease (GERD)

United States
Eisai Inc.

Terminated

Study of Perampanel as Adjunctive Treatment for Inadequately Controlled Seizures Associated With Lennox-Gastaut Syndrome

Lennox-Gastaut Syndrome (LGS)

Korea, Republic of, United States, Australia, Belgium, Japan, Czechia, India
Eisai Inc.

Completed

A Study of Subcutaneous Lecanemab in Healthy Participants

Healthy Volunteers

United States
Eisai Inc.

Completed

A Study to Evaluate Lemborexant in Milk of Healthy Lactating Women

Healthy Volunteers

United States
Eisai Inc.

Completed

A Study to Assess the Efficacy and Safety of Farletuzumab (MORAb 003) in Combination With Carboplatin Plus Paclitaxel or Carboplatin Plus Pegylated Liposomal Doxorubicin (PLD) in Participants With Low CA125 Platinum-sensitive Ovarian Cancer

Platinum-Sensitive Ovarian Cancer in First Relapse

United States, Italy, United Kingdom, Germany, Spain, Belgium, Japan

3

Subscribe